LifeTech’s Ankura™ Aortic Stent Graft System Receives China NMPA Approval

LifeTech Scientific Corporation ( (HK:1302) ) has issued an announcement.

LifeTech Scientific Corporation announced the official approval of its Ankura™ Aortic Stent Graft System by the China National Medical Products Administration. This system, co-developed with Fuwai Hospital, is the first of its kind to be applicable to the chimney technique, offering a safer and more effective treatment for aortic arch lesions. The approval marks a significant advancement in the company’s comprehensive solutions for aortic arch reconstruction and positions LifeTech to expand its market presence by meeting urgent clinical needs and benefiting a broad patient base.

More about LifeTech Scientific Corporation

LifeTech Scientific Corporation operates in the medical device industry, focusing on innovative endovascular solutions. The company develops and manufactures products such as the Ankura™ Aortic Stent Graft System, aiming to improve treatment options for patients with cardiovascular conditions.

YTD Price Performance: 2.88%

Average Trading Volume: 22,541,852

Technical Sentiment Consensus Rating: Buy

Current Market Cap: HK$6.39B

For an in-depth examination of 1302 stock, go to TipRanks’ Stock Analysis page.